$8.13
0.172.14%
At Close: -
$8.13
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Outlook Therapeutics
OTLKNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Outlook Therapeutics (NASDAQ:OTLK) Stock, Analyst Ratings, Price Targets, Forecasts
Outlook Therapeutics Inc has a consensus price target of $11.82 based on the ratings of 9 analysts. The high is $50 issued by BTIG on March 27, 2024. The low is $1 issued by Cantor Fitzgerald on August 30, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and HC Wainwright & Co. on May 17, 2024, March 27, 2024, and March 25, 2024, respectively. With an average price target of $36.67 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 351.00% upside for Outlook Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Chardan Capital
Guggenheim
Brookline Capital
1calculated from analyst ratings
Analyst Ratings for Outlook Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/17/2024 | Buy Now | 269% | HC Wainwright & Co. | Douglas Tsao | → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 515.01% | BTIG | Julian Harrison | → $50 | Upgrade | Neutral → Buy | Get Alert |
| 03/25/2024 | Buy Now | 269% | HC Wainwright & Co. | Douglas Tsao | $1.5 → $30 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | -63.1% | Chardan Capital | Daniil Gataulin | → $60 | Upgrade | Neutral → Buy | Get Alert |
| 01/25/2024 | Buy Now | -75.4% | Guggenheim | Eddie Hickman | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 01/25/2024 | Buy Now | -80.69% | Brookline Capital | Kemp Dolliver | → $31.4 | Upgrade | Hold → Buy | Get Alert |
| 12/29/2023 | Buy Now | -75.4% | Ascendiant Capital | Edward Woo | $30 → $40 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | -38.5% | Capital One | Zegbeh Jallah | → $100 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/03/2023 | Buy Now | -75.4% | HC Wainwright & Co. | Douglas Tsao | $20 → $40 | Maintains | Buy | Get Alert |
| 08/31/2023 | Buy Now | — | Chardan Capital | Daniil Gataulin | — | Downgrade | Buy → Neutral | Get Alert |
| 08/31/2023 | Buy Now | -87.7% | HC Wainwright & Co. | Douglas Tsao | → $20 | Downgrade | Buy → Neutral | Get Alert |
| 08/30/2023 | Buy Now | — | Brookline Capital | Kumaraguru Raja | — | Downgrade | Buy → Hold | Get Alert |
| 08/30/2023 | Buy Now | -87.7% | Cantor Fitzgerald | Kristen Kluska | $90 → $20 | Downgrade | Overweight → Neutral | Get Alert |
| 08/30/2023 | Buy Now | — | BTIG | Julian Harrison | — | Downgrade | Buy → Neutral | Get Alert |
| 08/15/2023 | Buy Now | -38.5% | HC Wainwright & Co. | Douglas Tsao | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 23% | Chardan Capital | Daniil Gataulin | → $200 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | -38.5% | HC Wainwright & Co. | Douglas Tsao | → $100 | Reiterates | Buy → Buy | Get Alert |
| 07/13/2023 | Buy Now | -38.5% | Capital One | Zegbeh Jallah | → $100 | Initiates | → Overweight | Get Alert |
| 05/16/2023 | Buy Now | 23% | Chardan Capital | Daniil Gataulin | → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | -38.5% | HC Wainwright & Co. | Douglas Tsao | → $100 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | -38.5% | Guggenheim | Eddie Hickman | → $100 | Initiates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | -38.5% | HC Wainwright & Co. | Douglas Tsao | → $100 | Maintains | Buy | Get Alert |
| 02/06/2023 | Buy Now | -50.8% | Cantor Fitzgerald | Kristen Kluska | → $80 | Initiates | → Overweight | Get Alert |
| 01/06/2023 | Buy Now | -38.5% | HC Wainwright & Co. | Douglas Tsao | $120 → $100 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | -13.9% | BTIG | Julian Harrison | → $140 | Initiates | → Buy | Get Alert |
| 09/13/2022 | Buy Now | 23% | Chardan Capital | Daniil Gataulin | → $200 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Outlook Therapeutics (OTLK) stock?
The latest price target for Outlook Therapeutics (NASDAQ:OTLK) was reported by HC Wainwright & Co. on May 17, 2024. The analyst firm set a price target for $30.00 expecting OTLK to rise to within 12 months (a possible 269.00% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Outlook Therapeutics (OTLK)?
The latest analyst rating for Outlook Therapeutics (NASDAQ:OTLK) was provided by HC Wainwright & Co., and Outlook Therapeutics reiterated their buy rating.
When was the last upgrade for Outlook Therapeutics (OTLK)?
The last upgrade for Outlook Therapeutics Inc happened on March 27, 2024 when BTIG raised their price target to $50. BTIG previously had a neutral for Outlook Therapeutics Inc.
When was the last downgrade for Outlook Therapeutics (OTLK)?
The last downgrade for Outlook Therapeutics Inc happened on August 31, 2023 when Chardan Capital changed their price target from N/A to N/A for Outlook Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Outlook Therapeutics (OTLK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outlook Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outlook Therapeutics was filed on May 17, 2024 so you should expect the next rating to be made available sometime around May 17, 2025.
Is the Analyst Rating Outlook Therapeutics (OTLK) correct?
While ratings are subjective and will change, the latest Outlook Therapeutics (OTLK) rating was a reiterated with a price target of $30.00 to $30.00. The current price Outlook Therapeutics (OTLK) is trading at is $8.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.